R205
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 80
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.510
- UNFOLDED_PROTEIN_RESPONSE+0.480
- MYC_TARGETS_V1+0.460
- TGF_BETA_SIGNALING+0.420
- MYC_TARGETS_V2+0.410
- MTORC1_SIGNALING+0.360
- OXIDATIVE_PHOSPHORYLATION+0.350
- ANDROGEN_RESPONSE+0.340
- DNA_REPAIR+0.320
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.320
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.430
- INTERFERON_GAMMA_RESPONSE-0.380
- ALLOGRAFT_REJECTION-0.350
- INFLAMMATORY_RESPONSE-0.350
- KRAS_SIGNALING_DN-0.340
- IL6_JAK_STAT3_SIGNALING-0.320
- APICAL_SURFACE-0.250
- COMPLEMENT-0.220
- PANCREAS_BETA_CELLS-0.180
- COAGULATION-0.170
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR12696786 | — | — | 0.856 |
| 2 | SRR23303753 | — | — | 0.854 |
| 3 | 47757643-A7B2-4782-8DAF-AE56BE8777D2 | — | — | 0.852 |
| 4 | 28B7B2FC-8270-42E3-95ED-4CC4F0979EE9 | — | — | 0.837 |
| 5 | A3153235-3128-40AC-9371-AFA1F61E3E59 | — | — | 0.836 |
| 6 | DRR168536 | — | — | 0.834 |
| 7 | SRR650181 | — | — | 0.832 |
| 8 | MNG666 | — | — | 0.831 |
| 9 | SAMN03290906 | — | — | 0.831 |
| 10 | TCGA-33-4586-01A-01R-1443-07 | — | cohortSQ2 | 0.831 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 29 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.510 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.480 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.460 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.420 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.410 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.360 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.350 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.340 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.320 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.320 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.310 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.300 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.300 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.300 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.260 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.260 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.240 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.240 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.230 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.210 | Remibrutinib | — uncovered |